Dr. Robert Gundel joins Amorfix as Vice President, Research & Development
Amorfix Life Sciences announced that Robert Gundel, Ph.D., M.B.A., has been appointed the company's Vice President, Research & Development.
Dr. Gundel has 25 years of drug development experience with both major pharmaceutical and smaller biotechnology companies focusing on therapeutic monoclonal antibodies and vaccines. Before joining Amorfix, Dr. Gundel was the Chief Scientific Officer at Heat Biologics, a clinical stage company developing novel vaccine and monoclonal antibody technologies for the treatment of autoimmune diseases and cancers. Prior to Heat Biologics, Dr. Gundel was the Vice President and Head of Research at Elusys Therapeutics Inc. where he directed all research and development programs in the areas of vaccines, anti-infectives and the anti-anthrax toxin monoclonal antibody, Anthem(TM), being developed in collaboration with the National Institute of Allergy and Infectious Diseases and the Department of Homeland Security for stockpiling as part of the U.S. biodefense program against potential terrorist attacks. Prior to that, Dr. Gundel was the Chief Scientific Officer at Arius Research, Inc. which was recently purchased by Roche. Earlier in his career, Dr. Gundel served as Vice President, Pharmacology and Preclinical Research at Chiron Corporation, Director of Pharmacology at Bayer Corporation, and Vice President, Preclinical Research and Scientific Corporate Development at XOMA (US), LLC. He began his career in pharmaceutical R&D at Boehringer Ingelheim Pharmaceuticals, Inc.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
